• Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line).
  
• Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
  

DOI=10.5282/edoc.26548
Messner M.
Sorafenib resistance of hepatocellular carcinoma: antibiotics second- line to sorafenib therapy inhibit mitochondrial biogenesis and prevent tumor growth resumption.
Thesis PhD (2020); Ludwig Maximilians University of Munich; Munich; Germany

PubMed=32652772; DOI=10.1096/fj.202001128R
Messner M., Schmitt S., Ardelt M.A., Frohlich T., Muller M., Pein H., Huber-Cantonati P., Ortler C., Koenig L.M., Zobel L., Koeberle A., Arnold G.J., Rothenfusser S., Kiemer A.K., Gerbes A.L., Zischka H., Vollmar A.M., Pachmayr J.
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.
FASEB J. 34:11860-11882(2020)